UNSPSC 51294802: Rofelodine

This classification denotes an antidepressant agent with the molecular formula C13H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 146D7G2I94, chemically known as 2,6,7,8-tetrahydro-7-phenylpyrrolo(1,2-a)pyrimidin-4(3h)-one but generally known as rofelodine, which bears US NIH Compound Identifier 71152. European Medicines Agency schedules Rofelodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10356MIG.

UNSPSC 51294802 Rofelodine is a Commodity code that in practice encompasses a broader range of pharmaceutical and drug-related products than its narrow name suggests. Recent state and local solicitations under this code show procurement of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesale channels and direct-to-manufacturer arrangements. State and local health agencies, cooperative purchasing alliances, and county health departments drive demand under this code, with procurement structured as competitive bidding through IFBs, RFPs, and RFIs that emphasize compliance with FDA requirements, Good Manufacturing Practices, and Drug Supply Chain Security Act standards. Vendors must typically maintain relationships with authorized pharmaceutical wholesalers, submit detailed product and pricing data in standardized formats, and carry comprehensive liability and workers' compensation insurance.

Activity clusters in Florida and Minnesota, with broader multistate reach through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. None of the recent solicitations identified explicit set-aside designations for disadvantaged enterprises.